Roche Schizophrenia Medicine at Risk After Failing in Two Trials - Businessweek

[INCIID News Feed]

Business Recorder
<img alt="" height="1" width="1" />
Roche Schizophrenia Medicine at Risk After Failing in Two Trials
Businessweek
Roche Holding AG (ROG)&#39;s experimental schizophrenia drug bitopertin failed in two of six final-stage patient trials, putting its future at risk. Adding bitopertin to an anti-psychotic therapy didn&#39;t help patients overcome negative symptoms such as social ...
Roche Says Schizophrenia Treatment Fails Final Stage Clinical TestsWall Street Journal
UPDATE 1-Roche&#39;s schizophrenia drug misses goal in two late-stage trialsReuters UK
Roche&#39;s schizophrenia drug fails in two late-stage trialsBusiness Recorder
Reuters India
all 13 news articles &raquo;


More...